Mirum Pharmaceuticals

Investment area

Venture Investments


North America

Date of investment

October 2018

The pipeline of Mirum Pharmaceuticals consists of two clinical-stage product candidates with mechanisms of action that have potential utility across a wide range of rare liver diseases. We are advancing our lead candidate, maralixibat for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC) — conditions with a profound and devastating impact on quality of life for young patients and their families.

Visit site